Scholarlink

Purpose <p>This study was designed to investigate the clinical feasibility of [<sup>18</sup>F]AlF-FAP-NUR, including the pharmacokinetics, radiation dosimetry estimation, and the head-to-head comparison with [<sup>18</sup>F]FDG. The head-to-head comparison study was designed to investigate the radiotracer uptake of [<sup>18</sup>F]AlF-FAP-NUR, to detect the primary and metastatic lesions in patients with various solid cancers, and to compare the results with those of [<sup>18</sup>F]FDG PET/CT. The correlation of FAP-expression (H-scores) and standardized uptake values (SUVs) derived from [<sup>18</sup>F]AlF-FAP-NUR were also included.</p> Methods <p>Ten patients participated in a multi-time-point imaging protocol aimed at assessing pharmacokinetics and estimating radiation dosimetry. Radiation dosimetry calculations were performed using the OLINDA/EXM 2.0 software. For the comparative analysis between [<sup>18</sup>F]AlF-FAP-NUR and [<sup>18</sup>F]FDG PET, a cohort of 35 patients was included. SUVs and tumor-to-background ratios (TBRs) for primary and metastatic lesions were systematically collected and analyzed. To evaluate FAP expression in tissue samples, H-scores were obtained from FAP-immunohistochemistry (FAP-IHC) analyses of samples from 28 patients and correlated with the SUVs measured in [<sup>18</sup>F]AlF-FAP-NUR PET scans. Statistical analyses included non-parametric tests and correlation assessments, with a significance threshold set at <i>P</i> &lt; 0.05.</p> Results <p>The study of multi-time-point imaging demonstrated that tumor SUV<sub>max</sub> and TBRs increased over time, quickly peaking and remaining in a plateau phase [<sup>18</sup>F]AlF-FAP-NUR was mainly excreted from kidneys. The effective radiation dose of [<sup>18</sup>F]AlF-FAP-NUR was approximately 1.90E-02 mSv/MBq. In the head-to-head comparative study, [<sup>18</sup>F]AlF-FAP-NUR exhibited excellent detection capabilities for both primary and metastatic lesions, particularly in lymph node, bone, and lung metastases. The sensitivity and specificity of [<sup>18</sup>F]AlF-FAP-NUR PET/CT imaging for detecting lesions, as confirmed by pathology, were 86.7% and 98.3%, respectively. The positive predictive value (PPV) reached 89.7%, more than double that of [<sup>18</sup>F]FDG (PPV for FDG: 42.3%). Correlation analysis of the SUVs of [<sup>18</sup>F]AlF-FAP-NUR and FAP expression (based on H-score) showed that SUVs were all strongly correlated with FAP expression, with the SUV<sub>max</sub> correlation value being as high as 0.7729 (<i>P</i> &lt; 0.001).</p> Conclusion <p>Our pilot study in patients with various solid tumors has demonstrated acceptable radiation dosimetry, favorable biodistribution, and significant [<sup>18</sup>F]AlF-FAP-NUR uptake in FAP-expressing tumors. The strong correlation with FAP expression further indicates the potential clinical usability of [<sup>18</sup>F]AlF-FAP-NUR PET.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical comprehensive evaluation of [18F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [18F]FDG

  • 期刊论文

  • 发表日期：

    2025年3月8日

查看全文
  • Ziqi Zhang,
  • Shaoyu Liu,
  • Sihao Liang,
  • Xuejing Bai,
  • Yulu He,
  • Jiawei Zhong,
  • Wanmei Liang,
  • Peng Hou,
  • Huizhen Zhong,
  • Tingfan Wu,
  • Yee Ling Ng,
  • Jing Zhang,
  • Miao Ke,
  • Yimin Fu,
  • Xinlu Wang

摘要

Purpose

This study was designed to investigate the clinical feasibility of [18F]AlF-FAP-NUR, including the pharmacokinetics, radiation dosimetry estimation, and the head-to-head comparison with [18F]FDG. The head-to-head comparison study was designed to investigate the radiotracer uptake of [18F]AlF-FAP-NUR, to detect the primary and metastatic lesions in patients with various solid cancers, and to compare the results with those of [18F]FDG PET/CT. The correlation of FAP-expression (H-scores) and standardized uptake values (SUVs) derived from [18F]AlF-FAP-NUR were also included.

Methods

Ten patients participated in a multi-time-point imaging protocol aimed at assessing pharmacokinetics and estimating radiation dosimetry. Radiation dosimetry calculations were performed using the OLINDA/EXM 2.0 software. For the comparative analysis between [18F]AlF-FAP-NUR and [18F]FDG PET, a cohort of 35 patients was included. SUVs and tumor-to-background ratios (TBRs) for primary and metastatic lesions were systematically collected and analyzed. To evaluate FAP expression in tissue samples, H-scores were obtained from FAP-immunohistochemistry (FAP-IHC) analyses of samples from 28 patients and correlated with the SUVs measured in [18F]AlF-FAP-NUR PET scans. Statistical analyses included non-parametric tests and correlation assessments, with a significance threshold set at P < 0.05.

Results

The study of multi-time-point imaging demonstrated that tumor SUVmax and TBRs increased over time, quickly peaking and remaining in a plateau phase [18F]AlF-FAP-NUR was mainly excreted from kidneys. The effective radiation dose of [18F]AlF-FAP-NUR was approximately 1.90E-02 mSv/MBq. In the head-to-head comparative study, [18F]AlF-FAP-NUR exhibited excellent detection capabilities for both primary and metastatic lesions, particularly in lymph node, bone, and lung metastases. The sensitivity and specificity of [18F]AlF-FAP-NUR PET/CT imaging for detecting lesions, as confirmed by pathology, were 86.7% and 98.3%, respectively. The positive predictive value (PPV) reached 89.7%, more than double that of [18F]FDG (PPV for FDG: 42.3%). Correlation analysis of the SUVs of [18F]AlF-FAP-NUR and FAP expression (based on H-score) showed that SUVs were all strongly correlated with FAP expression, with the SUVmax correlation value being as high as 0.7729 (P < 0.001).

Conclusion

Our pilot study in patients with various solid tumors has demonstrated acceptable radiation dosimetry, favorable biodistribution, and significant [18F]AlF-FAP-NUR uptake in FAP-expressing tumors. The strong correlation with FAP expression further indicates the potential clinical usability of [18F]AlF-FAP-NUR PET.